TMCnet News

Global Bladder Cancer Therapeutics Market to Grow at a CAGR of 4.7% by 2021 - Key Vendors are Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche & Pfizer - Research and Markets

[June 08, 2017]

Global Bladder Cancer Therapeutics Market to Grow at a CAGR of 4.7% by 2021 - Key Vendors are Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche & Pfizer - Research and Markets

Research and Markets has announced the addition of the "Global Bladder Cancer Therapeutics Market 2017-2021" report to their offering.

The global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.

The report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is advent of novel pipeline. The global bladder cancer therapeutics market is expected to grow due to the presence of novel therapies in the early stages of the pipeline. For instance, the adoptive cell therapy utilizes the immunotherapy approach for the treatment of bladder cancer.

According to the report, one driver in the market is growing prevalence rate leads to higher prescription value. Bladder cancer is the ninth-most type of cancer diagnosed worldwide, with the highest incidence rates demonstrated by males in Southern and Western Europe, North America, and in certain countries in Northern Africa or Western Asia. Bladder cancer ranked among 15 most common causes of deaths worldwide.

Key vendors